Gyre Therapeutics (GYRE) Interest Expenses (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Interest Expenses of $844000.0 for Q1 2026, up 32.91% year-over-year from $635000.0 in Q1 2025, and up 228.4% quarter-over-quarter from $257000.0 in Q4 2025.
Gyre Therapeutics (GYRE) Interest Expenses (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Interest Expenses for 15 consecutive years, with $844000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 32.91% year-over-year to $844000.0; the TTM figure through Mar 2026 stood at $844000.0 (up 32.91% YoY), while the FY2025 annual figure was $88.6 million, down 53.47% from the prior year.
- Interest Expenses rose to $844000.0 in Q1 2026 per GYRE's latest filing, from $257000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $2.1 million in Q2 2024 and bottomed at -$905000.0 in Q4 2022.
- Historically, Interest Expenses has averaged $621588.2 across 5 years, with a median of $502000.0 in 2022.
- Annual changes were most pronounced in 2022 — Interest Expenses plunged 236.3% — and 2023, when it soared 1916.67%.
- Gyre Therapeutics' Interest Expenses stood at -$905000.0 in 2022, then jumped by 123.09% to $209000.0 in 2023, then grew by 15.31% to $241000.0 in 2024, then climbed by 6.64% to $257000.0 in 2025, then soared by 228.4% to $844000.0 in 2026.
- Business Quant data shows GYRE's Interest Expenses at $844000.0 in Q1 2026, $257000.0 in Q4 2025, and $1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 4.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.29 Mn |
| Jun 30, 2026 | 4.29 Mn |
| Mar 31, 2026 | 844,000.00 |
| Mar 31, 2026 | 844,000.00 |
| Dec 31, 2025 | 257,000.00 |
| Dec 31, 2025 | 257,000.00 |
| Sep 30, 2025 | 1.21 Mn |
| Sep 30, 2025 | 1.21 Mn |
| Jun 30, 2025 | 1.45 Mn |
| Jun 30, 2025 | 1.45 Mn |
| Mar 31, 2025 | 635,000.00 |
| Mar 31, 2025 | 635,000.00 |
| Dec 31, 2024 | 241,000.00 |
| Dec 31, 2024 | 241,000.00 |
| Sep 30, 2024 | 1.91 Mn |
| Sep 30, 2024 | 1.91 Mn |
| Jun 30, 2024 | 2.09 Mn |
| Jun 30, 2024 | 2.09 Mn |
| Mar 31, 2024 | 315,000.00 |
| Mar 31, 2024 | 315,000.00 |